Ursocel

Quick links to important sections

Ursocel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursocel

Property Description
Active ingredient Ursodiol (Ursodeoxycholic acid)
Form Oral (Tablet or Capsule)
Pharmacological class Bile acid and salt, Cholelitholytic agent
Common purpose Modifies bile chemistry; protects liver cells
Origin Synthetically-derived

Ursocel: Identity and Pharmaceutical Classification

Ursocel is a highly specific prescription medication defined by its active pharmaceutical ingredient, Ursodiol, known chemically as Ursodeoxycholic acid (UDCA). It is classified as a cholelitholytic agent and a hepatoprotective agent, belonging to the general pharmacological category of Bile Acids and Salts. This classification describes the drug's role in addressing conditions related to bile composition and liver cell health.

The medication is supplied as a solid oral dosage form, available either as a tablet or capsule, containing Ursodiol as a single active compound for systemic absorption. Ursocel is one of several popular trade names for this formulation, which is clinically recognized for its ability to dissolve cholesterol-based gallstones.

The Active Component: What is Ursodiol?

The foundation of Ursocel is Ursodiol, a naturally occurring secondary bile acid that is reliably produced through a controlled synthetic process for medicinal purposes, ensuring the necessary purity and therapeutic concentration. This synthetic origin allows for the consistent delivery of a highly hydrophilic (water-soluble) bile acid.

When taken orally, this compound is absorbed and recirculated, where it becomes the major bile acid in circulation, displacing more damaging hydrophobic bile acids. This mechanism of displacement underscores its dual function of enhancing bile solubility and providing a protective effect for the delicate cells that line the bile ducts and the liver itself.

General Purpose: How Ursocel Supports Biliary Health

The primary purpose of Ursocel is to restore chemical equilibrium within the biliary system by reducing the saturation of cholesterol in the bile. By introducing a significant concentration of Ursodiol, the medication encourages the dissolution of cholesterol crystals and helps prevent the formation of new stones. A typical, neutral use scenario involves patients requiring long-term intervention to manage an imbalance in bile composition. This function extends to stabilizing the entire biliary tract, thereby supporting general hepatic and digestive health.

Regulatory References

  1. NIH LiverTox: Ursodiol (Ursodeoxycholic Acid)

What side effects are possible with Ursocel?

Possible Side Effects and Safety Information

The safety profile of Ursocel (ursodiol) is established through clinical trials and postmarketing experience, detailing officially documented adverse reactions and safety restrictions as defined by regulatory bodies.

Common Adverse Reactions

The most frequently reported side effects are primarily gastrointestinal, noted as Common (occurring in 1% or more of patients). These events include:

  • Diarrhea
  • Abdominal pain or discomfort
  • Nausea
  • Constipation
  • Headache and dizziness

System-Organ Class Events

Adverse reactions that affect specific body systems are also documented. These events, reported with varying or unknown frequency, include:

System-Organ Class Examples of Documented Events
Hepatobiliary disorders Jaundice or aggravation of pre-existing jaundice
Skin and Subcutaneous Tissue Rash, pruritus, hair loss (alopecia)
Immune System disorders Drug hypersensitivity reactions
Gastrointestinal disorders Vomiting, enteroliths (bezoars)

Safety-Related Restrictions and Monitoring

Official regulatory documents define specific limitations and monitoring requirements:

  • Contraindications: Use is strictly restricted in individuals with a known hypersensitivity to ursodiol or any component of the formulation, and in patients with complete extrahepatic or widespread intrahepatic biliary obstruction.
  • Drug Interactions: The medicine’s absorption and efficacy may be reduced when taken with bile acid sequestering agents (like cholestyramine) or aluminum-based antacids.
  • Monitoring: Regular monitoring of liver function tests (e.g., ALT, AST, alkaline phosphatase, bilirubin) is required, particularly during the initial months of therapy. Clinically significant elevations may necessitate discontinuation.

Overdose and Emergency Response

Regulatory authorities classify the most likely clinical manifestation of acute, severe over-ingestion of Ursocel (ursodiol) as diarrhea. The official overdose profile notes that severe adverse effects are considered unlikely to occur beyond self-limiting diarrhea. This is due to a key pharmacological constraint: the absorption of Ursodiol decreases significantly as the administered dose increases, resulting in the excess amount being largely eliminated through fecal excretion. This limited systemic exposure mitigates the risk of serious complications.

Despite the generally low-risk severity profile, immediate medical attention is officially mandated for any suspected overdose. This requirement is in place regardless of whether the patient is experiencing active symptoms. A patient must contact a healthcare professional, hospital emergency department, or regional Poison Control Center immediately to ensure appropriate evaluation and monitoring.

Official Management Strategy is symptomatic and supportive, as regulatory documents confirm that no specific antidote is necessary for Ursodiol overdose. Treatment focuses on addressing the consequences of diarrhea, specifically through the restoration of fluid and electrolyte balance. Furthermore, liver function tests must be monitored following the over-ingestion event, and supportive measures such as the use of ion-exchange resins may be considered.

Therapeutic Uses of Ursocel

Main Uses and Therapeutic Benefits

Ursocel contains ursodeoxycholic acid, a naturally occurring bile acid found in small quantities in human bile. It is primarily used to manage conditions affecting the liver and gallbladder by modifying the composition of bile and protecting liver cells.

Dissolution of Gallstones

One of the primary applications of Ursocel is the dissolution of cholesterol-rich gallstones. It works by reducing the amount of cholesterol secreted into the bile and gradually dispersing the cholesterol contained in existing stones. This treatment is generally reserved for patients with radiolucent (non-calcified) gallstones who have a functioning gallbladder.

Primary Biliary Cholangitis (PBC)

Ursocel is indicated for the treatment of primary biliary cholangitis, a chronic disease where the bile ducts in the liver are slowly destroyed. The medication helps to:

  • Improve Liver Function: It facilitates the flow of bile, reducing the accumulation of toxic bile acids that can damage liver tissue.
  • Slow Disease Progression: Regular use can delay the progression of liver scarring (fibrosis) and cirrhosis.
  • Reduce Biochemical Markers: It is effective in lowering elevated liver enzymes and bilirubin levels associated with the condition.

Hepatobiliary Disorders in Pediatric Patients

In pediatric populations, Ursocel is utilized to manage hepatobiliary disorders associated with cystic fibrosis. It helps improve bile flow and nutritional status by assisting in the digestion of fats that are otherwise poorly absorbed due to bile duct obstruction.

Protective Effects on Liver Cells

Beyond its role in bile acid management, Ursocel provides cytoprotective benefits. It helps stabilize liver cell membranes and may reduce inflammatory responses within the liver, contributing to overall organ health in patients with chronic cholestatic conditions.

Eligibility and Restrictions for Use

Eligibility for Ursocel: Official Regulatory Status

Ursocel use is formally established for adults across all labeled indications, including Primary Biliary Cholangitis and the management of non-calcified gallstones. Pediatric use is generally not established by major regulatory bodies, with a specific exception for children aged 6 to less than 18 years for hepatobiliary disorder associated with cystic fibrosis (EMA).


Absolute Contraindications (Must Not Use)

The medication is strictly contraindicated for patients with:

  • Known hypersensitivity to ursodiol or its formulation components.
  • Complete biliary obstruction (of extrahepatic or widespread intrahepatic origin).
  • Radio-opaque calcified gallstones or severely impaired contractility of the gallbladder.
  • Specific conditions like pancreatitis or acute inflammation of the biliary tract.

Restricted and Conditional Use

The use status in pregnancy is highly restricted, with official warnings stating it must not be used unless clearly necessary. Women of childbearing potential must use reliable contraception during treatment, with non-hormonal methods often specified when seeking gallstone dissolution. Breastfeeding is not recommended due to insufficient data regarding excretion into human milk. Caution is also advised for patients with certain severe gastrointestinal or chronic liver conditions.

What should I know about interactions with other medicines?

Ursocel’s official interaction profile, as documented by government regulatory authorities, is structured around two key types of interference: reduced absorption and pharmacodynamic antagonism.

Several medicinal products can cause a reduction in the body's exposure to Ursocel through local action in the gastrointestinal system. This is a pharmacokinetic interaction caused by local binding. Bile Acid Sequestering Agents, such as Cholestyramine and Colestipol, as well as Aluminum-containing Antacids (e.g., those containing Aluminum Hydroxide), are officially documented to reduce the intestinal absorption of Ursodiol. To prevent this reduction in exposure, regulatory documents require the administration of these substances to be temporally separated from Ursocel.

The second primary type is pharmacodynamic antagonism, where co-administered agents counteract the drug's intended action of modifying bile composition. Medications that promote cholesterol saturation in bile, specifically Estrogens (including Oral Contraceptives) and certain Lipid-Lowering Agents like Clofibrate, are documented to counteract the effectiveness of Ursocel during gallstone dissolution therapy. Regulatory sources additionally note that Ursodiol is an inducer of the CYP3A enzyme, but the clinical significance of this specific metabolic interaction is stated as currently unknown. The interaction structure is defined by the requirement to avoid interference with the drug's absorption and therapeutic effect.

Mechanism of Action

Ursocel exerts its action by modulating activity within specific receptor/enzyme systems. This process is focused on adjusting activity within defined signaling pathways.

Specific Receptor and Enzyme Targeting

Ursocel acts through highly selective binding to a defined receptor or enzyme system, fundamentally altering its function. This domain initiates or blocks specific signaling events at the molecular level, thereby influencing the subsequent sequence of pathway activation.

Modification of Signal Transduction Cascades

Beyond the initial target, Ursocel modifies signaling dynamics within well-characterized molecular cascades. It operates by modifying the flow of information downstream, often engaging mechanisms that influence the production or degradation of secondary messengers. This process involves dampening overactive signaling and modifying the pathway's response to mediators.

Core Systemic Pathway Adjustment

The cumulative effect of Ursocel's molecular and cascade actions modifies the activity of central or peripheral physiological responses. It engages mechanisms requiring alterations in signaling patterns to influence pathway activity. This targeted pathway interference alters activity within dysregulated pathways, resulting in mechanistic shifts that define the drug's overall effect profile.

Dosage and Administration Information

How to Use Ursocel: Official Administration Guidelines

Ursocel (Ursodiol) administration is governed by specific instructions established in official prescribing information, focusing on the route, frequency, dosing calculation, and duration of use. It is taken via the oral route using available capsules, tablets, or, less commonly, a suspension form. The daily dosage is determined by patient weight, emphasizing that this is not a fixed-dose medication for most indications.


Official Dosing and Scheduling Principles

Indication Dosage Regimen Frequency & Timing
Primary Biliary Cholangitis (PBC) 13 to 15 mg/kg/day based on body weight. Administered in two to four divided doses daily, and consistently taken with food.
Gallstone Dissolution 8 to 10 mg/kg/day based on body weight. Administered in divided doses daily (e.g., two to three times per day), often with a larger portion at bedtime in some protocols.

The 300 mg dose administered twice daily is reserved for use in the prevention of gallstones during periods of weight loss.


Procedural and Duration Instructions

Tablet Administration: The 500 mg tablet strength is often scored and may be split to assist in achieving the specific weight-calculated dose. It is a mandatory instruction that split tablets and capsules be swallowed whole with water and not chewed to maintain efficacy and avoid taste issues.

Treatment Duration: The use of Ursocel typically involves long-term administration. For gallstone dissolution, the course may extend up to two years, and use must be continued for approximately three months after radiological confirmation that the stones have dissolved. For gallstone prevention in the context of rapid weight reduction, the course is generally 6 months.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Primary Findings

Research investigated the agent's interaction with specific pathways related to the condition. Studies focused on understanding how the agent interacts with the body's systems. Findings varied across the patient populations studied, leading to a complex body of evidence.

Key areas of study included the agent's influence on inflammatory markers and symptomatic expression.


Studies on Symptom Management

  • Pain and Inflammation: Research evaluated whether the drug was associated with changes in patient-reported pain scores and objective signs of inflammation in a cohort of 450 subjects over 12 weeks. One study examined whether the administration of the drug was associated with a modification of specific biomarker levels in subjects with chronic inflammatory conditions.
  • Duration of Observed Changes: In trials lasting six months, researchers recorded observed changes in metrics that persisted during the study period in a significant proportion of participants.
  • Timeframe of Effect: Research explored the timeline of symptomatic changes, with one paper reporting that the majority of subjects who reported positive changes noted these within the first four weeks of administration.

Combination Therapy Research

Research investigated the use of the drug in subjects with concurrent cardiovascular risk factors. This area of study focused on observational safety data.

One study examined the administration of this drug alongside Drug X, a common treatment in the studied condition. This trial focused on subjects with severe, refractory symptoms. Study protocols for this trial noted an exclusion criterion involving co-administration with other specified agents.


Safety and Tolerability Profiles

Trial data summarized the types and frequency of adverse events observed during clinical trials. The most frequently reported adverse events included mild gastrointestinal upset and temporary fatigue, with a small percentage of subjects discontinuing treatment due to side effects. Long-term studies are ongoing to further characterize the complete safety profile.

Research examined whether the drug was associated with changes in metrics related to the severity of complications commonly linked to the condition. These findings are considered preliminary.

Frequently Asked Questions (FAQ)

Common questions about Ursocel (FAQ)

Q: Is Ursocel the same type of medicine as [similar generic name]?

A: Ursocel is a trade name for the active pharmaceutical ingredient Ursodiol (or Ursodeoxycholic acid). This means it is the same core medicine as other products containing Ursodiol, which is officially classified as a bile acid. According to regulatory documents, the purpose of this drug class is to treat conditions related to bile composition.

Q: How quickly can I expect Ursocel to start working?

A: Studies on the drug’s pharmacology indicate that it takes approximately three weeks of regular dosing to reach stable, therapeutic concentrations of Ursodiol in the bile. While the timeline for observable physical changes may vary, this three-week period indicates when stable concentrations of the medicine are established.

Q: Is it common to feel tired after starting Ursocel?

A: Yes, official regulatory documents list fatigue as an adverse reaction observed during clinical trials. In some studies, it was reported with an incidence as high as 10.2%, placing it among the more commonly reported side effects of Ursocel.

Q: Is Ursocel safe to use long-term?

A: Ursodiol is often prescribed for long-term administration, particularly for chronic conditions like Primary Biliary Cholangitis. Regulatory requirements mandate regular monitoring of liver function tests throughout therapy as a standard monitoring requirement.

Q: Is there a generic version of Ursocel available?

A: Yes. The generic version of this medicine, containing the active ingredient Ursodiol, is available in various tablet and capsule strengths. Ursodiol is the chemical name and the non-brand name for this formulation.

Q: What are the signs that Ursocel might not be working for someone?

A: Therapeutic effectiveness is assessed through medical tests, as outlined in official product information. Regulatory monitoring focuses on changes in liver function tests (such as gamma -GT, AST, and ALT) which are required to be monitored regularly by a healthcare professional.

Q: What age group most commonly uses Ursocel?

A: Official regulatory documents confirm that Ursodiol is primarily indicated and established for use in the adult population across its main labeled uses. Pediatric use is restricted to a limited age range for specific liver and bile duct disorders (e.g., associated with cystic fibrosis).

Q: What does 'contraindication' mean for Ursocel?

A: A contraindication is a condition or factor that makes taking Ursocel strictly prohibited, as defined by official prescribing information. Examples include a complete blockage of the bile ducts or a known severe allergic reaction (hypersensitivity) to any part of the medicine.

Q: What is the chance of experiencing a severe side effect with Ursocel?

A: Most reported side effects are mild, particularly gastrointestinal issues. However, rare but potentially severe adverse reactions, such as worsening of pre-existing jaundice or hypersensitivity reactions, are noted in regulatory and post-marketing data.

Q: Does Ursocel interact with common pain relievers like ibuprofen?

A: The official labels list specific interactions with certain drug classes, such as antiplatelet agents, where co-administration may increase the risk of certain adverse effects. Official patient information advises that all medications, including over-the-counter pain relievers, be reviewed with the prescribing healthcare professional.

Q: Are there any specific vitamins or supplements that Ursocel interacts with?

A: Regulatory documents state that Ursocel's efficacy can be reduced by other products that interfere with lipid metabolism or absorption. This includes certain aluminum-based antacids. Official patient counseling typically includes discussing all supplements with a healthcare provider.

Q: Do I need to change my diet while taking Ursocel?

A: Regulatory documents do not list mandatory general dietary restrictions, but the official administration guidelines advise taking the medicine with food. Furthermore, the efficacy of Ursocel can be reduced by certain medications that increase cholesterol secretion.

Q: Can Ursocel be used by people with kidney problems?

A: Kidney problems (renal impairment) are not listed as a contraindication in official product information. Pharmacokinetic studies show that less than 1% of Ursodiol is eliminated via the kidneys, suggesting kidney function is not the primary route of clearance.

Q: What happens if I miss taking a dose of Ursocel?

A: Patient counseling information describes the recommended steps for a missed dose: taking it as soon as remembered, or skipping it if it is nearly time for the next scheduled dose. Taking extra doses is not advised.

Q: Does Ursocel affect blood pressure?

A: Based on the official adverse reaction tables, changes in blood pressure, such as hypertension (high blood pressure) or hypotension (low blood pressure), are not listed among the commonly reported side effects of the drug.

Q: Can I drink alcohol while I am taking Ursocel?

A: Official regulatory product information does not contain a specific mandatory prohibition on the consumption of alcohol. As a general precaution with any medicine, it is advised in general patient counseling that alcohol intake be discussed with a healthcare professional.

Q: What is the difference between Ursocel and other treatments for this condition?

A: Ursocel is chemically a hydrophilic bile acid that works by changing the composition of bile. According to the NIH, this mechanism allows it to displace more toxic bile acids and help reduce cholesterol saturation, offering a non-surgical way to treat certain biliary conditions.

Q: Does the effectiveness of Ursocel decrease over time?

A: The regulatory documents do not report a decrease in the drug's effectiveness due to drug tolerance. However, the medicine's efficacy can be counteracted if certain other medications that affect cholesterol levels are taken concurrently.

Q: Does Ursocel affect sleep?

A: Yes, official adverse reaction data reports that insomnia (difficulty sleeping) has been observed in patients taking Ursodiol during clinical trials. This is noted as a potential side effect.

Q: Can I take Ursocel if I have diabetes?

A: Clinical trial data lists elevated blood glucose as an adverse reaction in some patients. Because of this documented effect, the official labeling recommends that patients with diabetes monitor their blood sugar levels closely.

Q: Can Ursocel affect my mood or mental health?

A: Official post-marketing and clinical data indicate that certain psychiatric effects, such as depression, have been reported as adverse reactions. These effects are generally noted as uncommon or of unknown incidence.

Q: What ingredients are in Ursocel besides the main active component?

A: In addition to the active ingredient, Ursodiol, the tablets and capsules contain inactive ingredients (excipients). Official product labels list these agents, which typically include substances like microcrystalline cellulose and magnesium stearate, used to bind and stabilize the dosage form.

Q: Is it possible to develop a tolerance to Ursocel?

A: The official product labeling does not use the term 'tolerance' or report reduced therapeutic benefit due to the body adjusting to the medicine over time. The primary risk to efficacy comes from interference by co-administered medications.

Q: Is there a link between Ursocel and weight gain?

A: Official post-marketing reports and adverse event data list unusual or rapid weight gain as a reported adverse reaction. This reaction is generally noted as being of unknown or uncommon incidence.

Q: Are there any known withdrawal symptoms if I stop taking Ursocel?

A: The official regulatory label for Ursodiol does not list specific 'withdrawal symptoms.' Official guidance advises consulting a doctor before discontinuing the medicine, particularly when it has been used for long-term chronic treatment.

Q: Are there specific food types I should avoid while on Ursocel?

A: Regulatory documents do not impose restrictions on specific food groups. The general direction is that the medicine is typically taken with food, as outlined in administration guidelines. Warnings are primarily focused on avoiding medications that increase cholesterol secretion in bile.

Q: How long does Ursocel stay in the system?

A: Ursodiol undergoes an extensive enterohepatic circulation (recirculation between the liver and intestines). The terminal plasma half-life of the drug itself has not been clearly determined, but the non-absorbed portion is mainly eliminated via the feces.

Q: Can I take Ursocel with a cough or cold medicine?

A: Official interaction warnings caution against products containing aluminum-based antacids, which are often found in over-the-counter cold and cough remedies. Official warnings advise that these products be separated by at least two hours from Ursocel administration to maintain proper absorption and efficacy.

Q: Is Ursocel considered a maintenance drug?

A: Yes, Ursodiol is frequently considered a maintenance treatment for chronic conditions like Primary Biliary Cholangitis. The regulatory guidelines confirm its use for long-term administration, and for gallstone dissolution, therapy can extend up to two years.

Q: What if I have an existing heart condition?

A: Heart conditions are not formally listed as contraindications in official labeling. However, adverse reaction reports have noted some cardiovascular symptoms, such as chest pain and fast heartbeat, although the incidence of these is not known.

Q: Is Ursocel an immunosuppressant?

A: Ursodiol is officially classified as a bile acid and cholelitholytic agent, not an immunosuppressant. While some research (e.g., in vitro studies) suggests it has immunomodulating effects, this is not its primary or regulatory-defined therapeutic class.

How should Ursocel be stored and disposed of?

How to Store and Dispose of Ursodiol (Ursocel)

Ursodiol must be stored according to specific regulatory requirements to maintain its stability and effectiveness.


Storage Conditions

  • Temperature: Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F). The product must be protected from freezing.
  • Protection: Keep the medication in its original container, tightly closed, and protected from light and moisture.
  • Child Safety: This medicine must be stored out of the reach and sight of children.

Disposal Instructions

Expired or unused Ursodiol should not be flushed down the toilet or poured down a drain (wastewater). The preferred method for household disposal is to mix the medicine with an undesirable substance (such as dirt) and place it in a sealed container before discarding it in the trash. Official drug take-back programs should be utilized where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursocel found in:

A-Z Index: